Novel Biologic Targets Lupus MedPage Today Epratuzumab differs from rituximab in that it depletes only about 30% of B cells, she explained at the annual meeting of the British Society for Rheumatology. This partial depletion causes phosphorylation and internalization of CD22, a protein on the ... |
